Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model

Psychopharmacology

Volumn 215, Issue 2, 2011, Pages 367-377

  Karlsson, Louise ^a   Hiemke, Christoph ^b   Carlsson, Björn ^a   Josefsson, Martin ^c   Ahlner, Johan ^a,c   Bengtsson, Finn ^a   Schmitt, Ulrich ^b   Kugelberg, Fredrik C ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c National Board of Forensic Medicine   (Sweden)

Author keywords

abcb1ab; Blood brain barrier; Knockout mice; P glycoprotein; Pharmacodynamic; Pharmacokinetic; Venlafaxine

Indexed keywords

DRUG METABOLITE; GLYCOPROTEIN P; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG PENETRATION; ENANTIOMER; ENANTIOSELECTIVITY; EVENING DOSAGE; EXPLORATORY BEHAVIOR; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MORNING DOSAGE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REARING; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD-BRAIN BARRIER; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; P-GLYCOPROTEIN; STEREOISOMERISM; TIME FACTORS;

EID: 79955575024     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2148-5     Document Type: Article

References (63)

1. SV Ambudkar S Dey CA Hrycyna M Ramachandra I Pastan MM Gottesman 1999 Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 361 398 10331089 10.1146/annurev.pharmtox.39.1.361 1:CAS:528:DyaK1MXjtVejtLo%3D (Pubitemid 29222564)
2. G Apelqvist C Wikell B Hindfelt PBF Bergqvist G Andersson F Bengtsson 1999 Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges Psychopharmacology (Berl) 143 408 416 10.1007/s002130050966 1:CAS:528:DyaK1MXjs1eks7s%3D (Pubitemid 29222487)
3. DF Avgustinovich TV Lipina NP Bondar OV Alekseyenko NN Kudryavtseva 2000 Features of the genetically defined anxiety in mice Behav Genet 30 101 109 10979600 10.1023/A:1001999020138 1:STN:280:DC%2BD3cvpvFeiuw%3D%3D (Pubitemid 30660642)
4. GB Baker TI Prior 2002 Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs Ann Med 34 537 543 12553493 10.1080/078538902321117742 1:CAS:528:DC%2BD3sXhs1Wgtbs%3D (Pubitemid 36113811)
5. P Ballabh A Braun M Nedergaard 2004 The blood-brain barrier: an overview: structure, regulation, and clinical implications Neurobiol Dis 16 1 13 15207256 10.1016/j.nbd.2003.12.016 1:CAS:528:DC%2BD2cXjs1altL8%3D (Pubitemid 38569790)
6. P Baumann DF Zullin CB Eap 2002 Enantiomers' potential in psychopharmacology-a critical analysis with special emphasis on the antidepressant escitalopram Eur Neuropsychopharmacol 12 433 444 12208561 10.1016/S0924-977X(02)00051-2 1:CAS:528:DC%2BD38Xms1yhsLo%3D
7. M Brocco A Dekeyne S Veiga S Girardon MJ Millan 2002 Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents Pharmacol Biochem Behav 71 667 680 11888558 10.1016/S0091-3057(01)00701-8 1:CAS:528:DC%2BD38XhvVChur0%3D (Pubitemid 34219217)
8. C Cordon-Cardo JP O'Brien D Casals L Rittman-Grauer JL Biedler MR Melamed JR Bertino 1989 Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc Natl Acad Sci USA 86 695 698 2563168 10.1073/pnas.86.2.695 1:CAS:528:DyaL1MXovVWnsw%3D%3D (Pubitemid 19037807)
9. OL de Klerk FJ Bosker AT Willemsen A van Waarde AK Visser T de Jager G Dagyte JA den Boer RA Dierckx P Meerlo 2009 Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats J Psychopharmacol 24 1237 1242 19942635 10.1177/0269881109349840 1:CAS:528:DC%2BC3cXhtFahsL3J
10. RA de Oliveira GM Cunha KD Borges GS de Bruin EA dos Santos-Filho GS Viana VM de Bruin 2004 The effect of venlafaxine on behaviour, body weight and striatal monoamine levels on sleep-deprived female rats Pharmacol Biochem Behav 79 499 506 15582021 10.1016/j.pbb.2004.09.001 1:CAS:528:DC%2BD2cXhtVCltbvL (Pubitemid 39576167)
11. A Devault P Gros 1990 Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities Mol Cell Biol 10 1652 1663 1969610 1:CAS:528:DyaK3cXkslaitbk%3D
12. A Doran RS Obach BJ Smith NA Hosea S Becker E Callegari C Chen X Chen E Choo J Cianfrogna, et al. 2005 The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model Drug Metab Dispos 33 165 174 15502009 10.1124/dmd.104.001230 1:CAS:528:DC%2BD2MXltlentw%3D%3D (Pubitemid 40023528)
13. MJ Ehret GM Levin M Narasimhan A Rathinavelu 2007 Venlafaxine induces P-glycoprotein in human Caco-2 cells Hum Psychopharmacol 22 49 53 17191263 10.1002/hup.820 1:CAS:528:DC%2BD2sXisVKgtbY%3D (Pubitemid 46178778)
14. C Gentsch M Lichtsteiner H Feer 1987 Open field and elevated plus-maze: a behavioural comparison between spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats and the effects of chlordiazepoxide Behav Brain Res 25 101 107 3675823 10.1016/0166-4328(87)90003-9 1:STN:280:DyaL1c%2FltVSnuw%3D%3D (Pubitemid 17137690)
15. HK Gershenfeld SM Paul 1997 Mapping quantitative trait loci for fear-like behaviors in mice Genomics 46 1 8 9403052 10.1006/geno.1997.5002 1:CAS:528:DyaK2sXnvVCktbY%3D (Pubitemid 27527685)
16. M Gex-Fabry CB Eap B Oneda N Gervasoni JM Aubry G Bondolfi G Bertschy 2008 CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response Ther Drug Monit 30 474 482 18641553 1:CAS:528:DC%2BD1cXpsVCiu70%3D
17. S Hoffmeyer O Burk O von Richter HP Arnold J Brockmoller A Johne I Cascorbi T Gerloff I Roots M Eichelbaum U Brinkmann 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 3473 3478 10716719 10.1073/pnas.050585397 1:CAS:528:DC%2BD3cXitlWqtL8%3D (Pubitemid 30183327)
18. SM Holliday P Benfield 1995 Venlafaxine. A review of its pharmacology and therapeutic potential in depression Drugs 49 280 294 7729333 10.2165/00003495-199549020-00010 1:CAS:528:DyaK2MXkt1Citbg%3D
19. RH Howland 2009 Clinical implications of chirality and stereochemistry in psychopharmacology J Psychosoc Nurs Ment Health Serv 47 17 21
20. JC Kalvass ER Olson MP Cassidy DE Selley GM Pollack 2007 Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data J Pharmacol Exp Ther 323 346 355 17646430 10.1124/jpet.107. 119560 1:CAS:528:DC%2BD2sXhtFahsb%2FN (Pubitemid 47443282)
21. JC Kalvass ER Olson GM Pollack 2007 Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception Drug Metab Dispos 35 455 459 17178769 10.1124/dmd.106.011445 1:CAS:528:DC%2BD2sXisl2iur4%3D (Pubitemid 46333909)
22. L Karlsson U Schmitt M Josefsson B Carlsson J Ahlner F Bengtsson FC Kugelberg C Hiemke 2010 Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein Eur Neuropsychopharmacol 20 632 640 20466523 10.1016/j.euroneuro.2010.04.004 1:CAS:528:DC%2BC3cXps1ehurg%3D
23. M Kato T Fukuda A Serretti M Wakeno G Okugawa Y Ikenaga Y Hosoi Y Takekita L Mandelli J Azuma T Kinoshita 2008 ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder Prog Neuropsychopharmacol Biol Psychiatry 32 398 404 17913323 10.1016/j.pnpbp.2007.09.003 1:CAS:528:DC%2BD1cXhsVKitLk%3D (Pubitemid 351178955)
24. GA Kennett CT Dourish G Curzon 1987 Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression Eur J Pharmacol 134 265 274 2883013 10.1016/0014-2999(87)90357-8 1:CAS:528: DyaL2sXhvVyqs70%3D (Pubitemid 17033932)
25. RC Kessler S Aguilar-Gaxiola J Alonso S Chatterji S Lee J Ormel TB Ustun PS Wang 2009 The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys Epidemiol Psichiatr Soc 18 23 33 19378696
26. RB Kim BF Leake EF Choo GK Dresser SV Kubba UI Schwarz A Taylor HG Xie J McKinsey S Zhou LB Lan JD Schuetz EG Schuetz GR Wilkinson 2001 Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 189 199 11503014 10.1067/mcp.2001.117412 1:CAS:528:DC%2BD3MXmslygs7o%3D (Pubitemid 32777772)
27. M Kingbäck M Josefsson L Karlsson J Ahlner F Bengtsson FC Kugelberg B Carlsson 2010 Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction J Pharm Biomed Anal 53 583 590 20435422 10.1016/j.jpba.2010.03. 043 1:CAS:528:DC%2BC3cXptVSruro%3D
28. KM Kirschbaum S Henken C Hiemke U Schmitt 2008 Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice Behav Brain Res 188 298 303 18164477 10.1016/j.bbr.2007.11. 009 1:CAS:528:DC%2BD1cXhslOjtbs%3D
29. KM Kirschbaum M Uhr D Holthoewer C Namendorf C Pietrzik C Hiemke U Schmitt 2010 Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice Neuropharmacology 59 474 479 20599439 10.1016/j.neuropharm.2010.06.010 1:CAS:528:DC%2BC3cXht1SqsLfF
30. DL Kroetz C Pauli-Magnus LM Hodges CC Huang M Kawamoto SJ Johns D Stryke TE Ferrin J DeYoung T Taylor EJ Carlson I Herskowitz KM Giacomini AG Clark 2003 Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene Pharmacogenetics 13 481 494 12893986 10.1097/00008571-200308000-00006 1:CAS:528:DC%2BD3sXlvV2jt7Y%3D (Pubitemid 37034590)
31. FC Kugelberg G Apelqvist F Bengtsson 2002 Effects of chronic citalopram treatment on central and peripheral spontaneous open-field behaviours in rats Pharmacol Toxicol 90 303 310 12403051 10.1034/j.1600-0773.2002.900603.x 1:CAS:528:DC%2BD38Xlt1Wmur8%3D (Pubitemid 34713195)
32. FC Kugelberg G Apelqvist C Wikell F Bengtsson 2005 Open-field behavioural alterations in liver-impaired and sham-operated rats after acute exposure to the antidepressant venlafaxine Basic Clin Pharmacol Toxicol 97 155 161 16128909 10.1111/j.1742-7843.2005.pto-97385.x 1:CAS:528:DC%2BD2MXhtVejsbvM (Pubitemid 41291212)
33. FC Kugelberg G Apelqvist B Carlsson J Ahlner F Bengtsson 2006 Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin Basic Clin Pharmacol Toxicol 99 80 88 16867175 10.1111/j.1742-7843.2006.pto-449.x 1:CAS:528: DC%2BD28XnvF2msb4%3D (Pubitemid 44034399)
34. A Kumar R Garg V Gaur P Kumar 2010 Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice Brain Res 1311 73 80 19945444 10.1016/j.brainres.2009.11.050 1:CAS:528:DC%2BC3cXot1Cj
35. JS Lagas ML Vlaming AH Schinkel 2009 Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice Mol Interv 9 136 145 19592674 10.1124/mi.9.3.7 1:CAS:528:DC%2BD1MXhtVSmsrjM
36. G Luurtsema CF Molthoff AD Windhorst JW Smit H Keizer R Boellaard AA Lammertsma EJ Franssen 2003 (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation Nucl Med Biol 30 747 751 14499333 10.1016/S0969-8051(03)00078-7 1:CAS:528: DC%2BD3sXnt1Gkurc%3D (Pubitemid 37123132)
37. U Mayer E Wagenaar B Dorobek JH Beijnen P Borst AH Schinkel 1997 Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833 J Clin Invest 100 2430 2436 9366556 10.1172/JCI119784 1:CAS:528:DyaK2sXnsVymt7c%3D (Pubitemid 27514881)
38. S Moussavi S Chatterji E Verdes A Tandon V Patel B Ustun 2007 Depression, chronic diseases, and decrements in health: results from the World Health Surveys Lancet 370 851 858 17826170 10.1016/S0140-6736(07)61415-9 (Pubitemid 47362344)
39. EA Muth JT Haskins JA Moyer GE Husbands ST Nielsen EB Sigg 1986 Antidepressant biochemical profile of the novel bicyclic compound Wy-45, 030, an ethyl cyclohexanol derivative Biochem Pharmacol 35 4493 4497 3790168 10.1016/0006-2952(86)90769-0 1:CAS:528:DyaL2sXpsF2ksw%3D%3D (Pubitemid 17223283)
40. EA Muth JT Haskins JA Moyer TH Andree GEM Husbands 1991 Biochemical, neuropsychological, and behavioral effects of Wy-45, 233 and other identified metabolites of the antidepressant venlafaxine Drug Dev Res 23 191 199 10.1002/ddr.430230210 1:CAS:528:DyaK3MXkvVGht7k%3D
41. G Nikisch CB Eap P Baumann 2008 Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study Pharmacol Res 58 344 347 18940259 10.1016/j.phrs.2008. 09.010 1:CAS:528:DC%2BD1cXhsVChu77O
42. E Nowakowska K Kus 2005 Antidepressant and memory affecting influence of estrogen and venlafaxine in ovariectomized rats Arzneimittelforschung 55 153 159 15819387 1:CAS:528:DC%2BD2MXjtFymsb0%3D (Pubitemid 40460017)
43. E Nowakowska K Kus A Chodera 2003 Comparison of behavioural effects of venlafaxine and imipramine in rats Arzneimittelforschung 53 237 242 12785118 1:CAS:528:DC%2BD3sXktlOrtb4%3D (Pubitemid 36535377)
44. A Oganesian AD Shilling R Young-Sciame J Tran A Watanyar F Azam J Kao L Leung 2009 Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities Psychopharmacol Bull 42 47 63 19629022
45. M Reis J Lundmark H Björk F Bengtsson 2002 Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting Ther Drug Monit 24 545 553 12142641 10.1097/00007691-200208000- 00014 1:CAS:528:DC%2BD38XmsValu7o%3D (Pubitemid 34857910)
46. M Reis T Aamo O Spigset J Ahlner 2009 Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database Ther Drug Monit 31 42 56 19077925 10.1097/FTD.0b013e31819114ea 1:CAS:528:DC%2BD1MXpt1Cjsw%3D%3D
47. B Rochat P Baumann KL Audus 1999 Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium Brain Res 831 229 236 10412001 10.1016/S0006-8993(99)01461-4 1:CAS:528:DyaK1MXjsF2qurg%3D (Pubitemid 29336205)
48. R Sandstrom A Karlsson H Lennernas 1998 The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum J Pharm Pharmacol 50 729 735 9720621 10.1111/j.2042-7158.1998.tb07133.x 1:CAS:528:DyaK1cXltFGhsL0%3D (Pubitemid 28379266)
49. AH Schinkel JJ Smit O van Tellingen JH Beijnen E Wagenaar L van Deemter CA Mol MA van der Valk EC Robanus-Maandag HP te Riele, et al. 1994 Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 491 502 7910522 10.1016/0092-8674(94)90212-7 1:CAS:528:DyaK2cXkt1Knsbc%3D (Pubitemid 24153990)
50. AH Schinkel U Mayer E Wagenaar CA Mol L van Deemter JJ Smit MA van der Valk AC Voordouw H Spits O van Tellingen JM Zijlmans WE Fibbe P Borst 1997 Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc Natl Acad Sci USA 94 4028 4033 9108099 10.1073/pnas.94.8.4028 1:CAS:528:DyaK2sXis1akurk%3D (Pubitemid 27180493)
51. U Schmitt C Hiemke 1998 Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling Pharmacol Biochem Behav 59 807 811 9586835 10.1016/S0091-3057(97)00502-9 1:CAS:528: DyaK1cXislGrtLo%3D (Pubitemid 28237890)
52. SM Stahl MM Grady C Moret M Briley 2005 SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants CNS Spectr 10 732 747 16142213 (Pubitemid 41443048)
53. AH Swiergiel AJ Dunn 2007 Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests Pharmacol Biochem Behav 86 651 659 17360031 10.1016/j.pbb.2007.02.010 1:CAS:528:DC%2BD2sXmtVGhsLc%3D (Pubitemid 46829318)
54. T Takeuchi T Owa T Nishino C Kamei 2010 Assessing anxiolytic-like effects of selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors using the elevated plus maze in mice Methods Find Exp Clin Pharmacol 32 113 121 20401348 1:CAS:528:DC%2BC3cXnsl2ls7w%3D
55. M Tanabe I Ieiri N Nagata K Inoue S Ito Y Kanamori M Takahashi Y Kurata J Kigawa S Higuchi N Terakawa K Otsubo 2001 Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J Pharmacol Exp Ther 297 1137 1143 11356939 1:CAS:528:DC%2BD3MXjvVShs7k%3D (Pubitemid 32472514)
56. F Thiebaut T Tsuruo H Hamada MM Gottesman I Pastan MC Willingham 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 84 7735 7738 2444983 10.1073/pnas.84.21.7735 1:CAS:528:DyaL2sXmtlels7k%3D
57. CM Thiel CP Muller JP Huston RK Schwarting 1999 High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments Neuroscience 93 243 251 10430488 10.1016/S0306- 4522(99)00158-X 1:CAS:528:DyaK1MXktlenurg%3D (Pubitemid 29290704)
58. M Uhr MT Grauer 2003 abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice J Psychiatr Res 37 179 185 12650738 10.1016/S0022-3956(03)00022-0 (Pubitemid 36313270)
59. M Uhr T Steckler A Yassouridis F Holsboer 2000 Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption Neuropsychopharmacology 22 380 387 10700657 10.1016/S0893-133X(99)00095-0 1:CAS:528:DC%2BD3cXhsVajsbs%3D (Pubitemid 30105766)
60. M Uhr MT Grauer F Holsboer 2003 Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption Biol Psychiatry 54 840 846 14550684 10.1016/S0006-3223(03)00074-X 1:CAS:528:DC%2BD3sXnvFWisb8%3D (Pubitemid 37205136)
61. M Uhr A Tontsch C Namendorf S Ripke S Lucae M Ising T Dose M Ebinger M Rosenhagen M Kohli S Kloiber D Salyakina T Bettecken M Specht B Putz EB Binder B Muller-Myhsok F Holsboer 2008 Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression Neuron 57 203 209 18215618 10.1016/j.neuron.2007.11.017 1:CAS:528:DC%2BD1cXhvVSrt74%3D
62. C Wikell G Apelqvist S Hjorth J Kullingsjö PBF Bergqvist F Bengtsson 2002 Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy Eur Neuropsychopharmacol 12 327 336 12126872 10.1016/S0924- 977X(02)00044-5 1:CAS:528:DC%2BD38XlsVKlsb8%3D (Pubitemid 34753104)
63. WYETH (2009) Product Monograph - PRISTIQ® desvenlafaxine Extended-Release Tablets, Montreal, Canada. Submission Control No: 130257. Date of Revision: August 26, 2009.